Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
5.04
-0.19 (-3.63%)
Jul 24, 2026, 1:57 PM EDT - Market open
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $358.00K in the quarter ending March 31, 2026. In the year 2025, Seres Therapeutics had annual revenue of $789.00K.
Revenue (ttm)
$789.00K
Revenue Growth
n/a
P/S Ratio
42.89
Revenue / Employee
$17,379
Employees
66
Market Cap
48.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 53.48M |
| Immutep | 5.28M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| INmune Bio | 50.00K |
MCRB News
- 16 days ago - Seres Therapeutics Transcript: Study result - Transcripts
- 16 days ago - Seres Therapeutics Press release: Study result - Filings
- 16 days ago - Seres Therapeutics Slides: Study result - Filings
- 16 days ago - Seres Therapeutics Transcript: AGM 2026 - Transcripts
- 16 days ago - Seres Therapeutics announces top-line results from SER-155 trial - TheFly
- 16 days ago - Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment - GlobeNewsWire
- 4 weeks ago - Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis - GlobeNewsWire
- 4 weeks ago - Seres Therapeutics initiated with a Buy at H.C. Wainwright - TheFly